A new perspective of vasculogenic mimicry: EMT and cancer stem cells (review)

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1174-1180

  Fan, Yun Long ^a   Zheng, Min ^a   Tang, Ya Ling ^a   Liang, Xin Hua ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Cancer stem cell; Epithelial mesenchymal transition; Metastasis; Vasculogenic mimicry

Indexed keywords

CD34 ANTIGEN; GELATINASE A; GELATINASE B; OCCLUDIN; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CELL MIGRATION; DISEASE COURSE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HISTOLOGY; HUMAN; MICROCIRCULATION; ONCOGENE SRC; ONCOLOGICAL PARAMETERS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SURVIVAL RATE; TUMOR INVASION; TUMOR VOLUME; VASCULOGENIC MIMICRY;

EID: 84884484146     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1555     Document Type: Review

References (120)

1. Hillen F and Griffioen AW: Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26: 489-502, 2007.
2. Maniotis AJ, Folberg R, Hess A, etal: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752, 1999.
3. El Hallani S, Boisselier B, Peglion F, etal: A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133: 973-982, 2010.
4. van der Schaft DW, Hillen F, Pauwels P, etal: Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 65: 11520-11528, 2005.
5. Shirakawa K, Kobayashi H, Heike Y, etal: Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 62: 560-566, 2002.
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, etal: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
7. Wang W, Lin P, Han C, Cai W, Zhao X and Sun B: Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res 29: 60, 2010.
8. Upile T, Jerjes W, Radhi H, etal: Vascular mimicry in cultured head and neck tumour cell lines. Head Neck Oncol 3: 55, 2011.
9. Lin P, Wang W, Sun BC, etal: Vasculogenic mimicry is a key prognostic factor for laryngeal squamous cell carcinoma: a new pattern of blood supply. Chin Med J (Engl) 125: 3445-3449, 2012.
10. Francescone R, Scully S, Bentley B, etal: Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem 287: 24821-24831, 2012.
11. Shirakawa K, Wakasugi H, Heike Y, etal: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer99: 821-828, 2002.
12. Ponti D, Costa A, Zaffaroni N, etal: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511, 2005.
13. Tang HS, Feng YJ and Yao LQ: Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int J Gynecol Cancer19: 605-610, 2009.
14. Su M, Feng YJ, Yao LQ, etal: Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo. Int J Gynecol Cancer 18: 476-486, 2008.
15. Liu Z, Li Y, Zhao W, Ma Y and Yang X: Demonstration of vasculogenic mimicry in astrocytomas and effects of Endostar on U251 cells. Pathol Res Pract 207: 645-651, 2011.
16. Baeten CI, Hillen F, Pauwels P, de Bruine AP and Baeten CG: Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 52: 2028-2035, 2009.
17. Warso MA, Maniotis AJ, Chen X, etal: Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 7: 473-477, 2001.
18. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, etal: The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100: 1389-1398, 1993.
19. van der Schaft DW, Seftor RE, Seftor EA, etal: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96: 1473-1477, 2004.
20. Kalluri R and Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003.
21. Eccles SA and Welch DR: Metastasis: recent discoveries and novel treatment strategies. Lancet 369: 1742-1757, 2007.
22. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
23. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
24. Liu Z, Sun B, Qi L, Li H, Gao J and Leng X: Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci 103: 813-820, 2012.
25. Sun T, Zhao N, Zhao XL, etal: Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 51: 545-556, 2010.
26. Clarke MF, Dick JE, Dirks PB, etal: Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
27. Shipitsin M and Polyak K: The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 88: 459-463, 2008.
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
29. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
30. Rosen JM and Jordan CT: The increasing complexity of the cancer stem cell paradigm. Science 324: 1670-1673, 2009.
31. Singh SK, Hawkins C, Clarke ID, etal: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
32. Ricci-Vitiani L, Pallini R, Biffoni M, etal: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468: 824-828, 2010.
33. Wang R, Chadalavada K, Wilshire J, etal: Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468: 829-833, 2010.
34. Dong J, Zhao Y, Huang Q, etal: Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation. Stem Cell Rev 7: 141-152, 2011.
35. Mani SA, Guo W, Liao MJ, etal: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell133: 704-715, 2008.
36. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S and Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888, 2008.
37. Chen J, Li Y, Yu TS, etal: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-526, 2012.
38. Lapidot T, Sirard C, Vormoor J, etal: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648, 1994.
39. Hemmati HD, Nakano I, Lazareff JA, etal: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA100: 15178-15183, 2003.
40. Singh SK, Clarke ID, Terasaki M, etal: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003.
41. Fang D, Nguyen TK, Leishear K, etal: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337, 2005.
42. Schatton T, Murphy GF, Frank NY, etal: Identification of cells initiating human melanomas. Nature 451: 345-349, 2008.
43. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
44. Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029, 2005.
45. Alvero AB, Chen R, Fu HH, etal: Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle 8: 158-166, 2009.
46. Hermann P, Huber S, Herrler T, etal: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
47. Sun S and Wang Z: Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer 129: 2337-2348, 2011.
48. Monroe MM, Anderson EC, Clayburgh DR and Wong MH: Cancer stem cells in head and neck squamous cell carcinoma. J Oncol 2011: 762780, 2011.
49. Sayed SI, Dwivedi RC, Katna R, etal: Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol 47: 237-243, 2011.
50. Zito G, Richiusa P, Bommarito A, etal: In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 3: e3544, 2008.
51. Wang J, Guo LP, Chen LZ, Zeng YX and Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67: 3716-3724, 2007.
52. Prince ME, Sivanandan R, Kaczorowski A, etal: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978, 2007.
53. Prince ME and Ailles LE: Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 26: 2871-2875, 2008.
54. Balic M, Lin H, Young L, etal: Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12: 5615-5621, 2006.
55. Charafe-Jauffret E, Ginestier C, Iovino F, etal: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16: 45-55, 2010.
56. Davis SJ, Divi V, Owen JH, etal: Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 136: 1260-1266, 2010.
57. Faber A, Barth C, Hörmann K, etal: CD44 as a stem cell marker in head and neck squamous cell carcinoma. Oncol Rep26: 321-326, 2011.
58. Song J, Chang I, Chen Z, Kang M and Wang CY: Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling. PLoS One 5: e11456, 2010.
59. Goldie SJ, Mulder KW, Tan DW, Lyons SK, Sims AH and WattFM: FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis. Cancer Res 72: 3424-3436, 2012.
60. La Fleur L, Johansson AC and Roberg K: A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS One 7: e44071, 2012.
61. Tamara Marie-Egyptienne DT, Lohse I and Hill RP: Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett: Nov 28, 2012 (Epub ahead of print). doi: 10.1016/j.canlet.2012.11.019.
62. Todaro M, Alea MP, Di Stefano AB, etal: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402, 2007.
63. Cheung ST, Cheung PF, Cheng CK, Wong NC and Fan ST: Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 140: 344-355, 2011.
64. Bussolati B, Grange C, Sapino A and Camussi G: Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med 13: 309-319, 2009.
65. Hendrix MJ, Seftor EA, Meltzer PS, etal: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 98: 8018-8023, 2001.
66. Soda Y, Marumoto T, Friedmann-Morvinski D, etal: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 108: 4274-4280, 2011.
67. Lai CY, Schwartz BE and Hsu MY: CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res72: 5111-5118, 2012.
68. Frank NY, Schatton T, Kim S, etal: VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 71: 1474-1485, 2011.
69. Dang D and Ramos DM: Identification of αvβ6-positive stem cells in oral squamous cell carcinoma. Anticancer Res29: 2043-2049, 2009.
70. Zhang S, Guo H, Zhang D, etal: Microcirculation patterns in different stages of melanoma growth. Oncol Rep 15: 15-20, 2006.
71. Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
72. Nguyen PT, Kudo Y, Yoshida M, Kamata N, Ogawa I and TakataT: N-cadherin expression is involved in malignant behavior of head and neck cancer in relation to epithelial-mesenchymal transition. Histol Histopathol 26: 147-156, 2011.
73. Mandal M, Myers JN, Lippman SM, etal: Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112: 2088-2100, 2008.
74. Batlle E, Sancho E, Franci C, etal: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84-89, 2000.
75. Cano A, Pérez-Moreno MA, Rodrigo I, etal: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.
76. Zhang A, Chen G, Meng L, etal: Antisense-Snail transfer inhibits tumor metastasis by inducing E-cadherin expression. Anticancer Res 28: 621-628, 2008.
77. Hajra KM, Chen DY and Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62: 1613-1618, 2002.
78. Yang J, Mani SA, Donaher JL, etal: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell117: 927-939, 2004.
79. Zhang J, Liang Q, Lei Y, etal: SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res 72: 4597-4608, 2012.
80. Eger A, Aigner K, Sonderegger S, etal: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24: 2375-2385, 2005.
81. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005.
82. Porsch H, Bernert B, Mehic M, Theocharis AD, Heldin CH and Heldin P: Efficient TGFbeta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene: Oct29, 2012 (Epub ahead of print). doi: 10.1038/onc.2012.475.
83. Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG and Weiss SJ: Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer1, Early Onset (BRCA1) repression. Proc Natl Acad Sci USA109: 16654-16659, 2012.
84. Guaita S, Puig I, Franci C, etal: Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 277: 39209-39216, 2002.
85. Zhao XL, Sun T, Che N, etal: Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1. J Cell Mol Med 15: 691-700, 2011.
86. Tsai JH, Donaher JL, Murphy DA, Chau S and Yang J: Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell22: 725-736, 2012.
87. Aigner K, Dampier B, Descovich L, etal: The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene26: 6979-6988, 2007.
88. Wellner U, Schubert J, Burk UC, etal: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11: 1487-1495, 2009.
89. Ahn YH, Gibbons DL, Chakravarti D, etal: ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest 122: 3170-3183, 2012.
90. Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ and Yang J: Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res71: 245-254, 2011.
91. Sun T, Sun BC, Zhao XL, etal: Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 54: 1690-1706, 2011.
92. Lirdprapamongkol K, Chiablaem K, Sila-Asna M, Surarit R, Bunyaratvej A and Svasti J: Exploring stemness gene expression and vasculogenic mimicry capacity in well-and poorly-differentiated hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 422: 429-435, 2012.
93. Passegué E, Jamieson CH, Ailles LE and Weissman IL: Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 100 (Suppl 1): 11842-11849, 2003.
94. Prindull G: Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells? Exp Hematol 33: 738-746, 2005.
95. Notta F, Mullighan CG, Wang JC, etal: Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature469: 362-367, 2011.
96. Biddle A, Liang X, Gammon L, etal: Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 71: 5317-5326, 2011.
97. Damonte P, Gregg JP, Borowsky AD, Keister BA and CardiffRD: EMT tumorigenesis in the mouse mammary gland. Lab Invest87: 1218-1226, 2007.
98. Santisteban M, Reiman JM, Asiedu MK, etal: Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 69: 2887-2895, 2009.
99. Fang X, Cai Y, Liu J, etal: Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 30: 4707-4720, 2011.
100. Asiedu MK, Ingle JN, Behrens MD, Radisky DC and KnutsonKL: TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 71: 4707-4719, 2011.
101. Ryu HS, Park do J, Kim HH, Kim WH and Lee HS: Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 43: 520-528, 2012.
102. Sarkar D, Shields B, Davies ML, Muller J and Wakeman JA: BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. Int J Cancer 130: 328-337, 2012.
103. Xia H, Cheung WK, Sze J, etal: miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J Biol Chem 285: 36995-37004, 2010.
104. Chen YC, Chen YW, Hsu HS, etal: Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 385: 307-313, 2009.
105. Chen YS, Wu MJ, Huang CY, etal: CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One 6: e28053, 2011.
106. Hendrix MJ, Seftor EA, Hess AR and Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421, 2003.
107. Pisacane AM, Picciotto F and Risio M: CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiation in human cutaneous melanoma. Cell Oncol29: 59-66, 2007.
108. Garnier D, Milsom C, Magnus N, etal: Role of the tissue factor pathway in the biology of tumor initiating cells. Thromb Res125 (Suppl 2): S44-S50, 2010.
109. Gill JG, Langer EM, Lindsley RC, Cai M, Murphy TL and Murphy KM: Snail promotes the cell-autonomous generation of Flk1(+) endothelial cells through the repression of the microRNA-200 family. Stem Cells Dev 21: 167-176, 2012.
110. Sun B, Zhang D, Zhang S, Zhang W, Guo H and Zhao X: Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249: 188-197, 2007.
111. Ma JL, Han SX, Zhu Q, etal: Role of Twist in vasculogenic mimicry formation in hypoxic hepatocellular carcinoma cells in vitro. Biochem Biophys Res Commun 408: 686-691, 2011.
112. Comito G, Calvani M, Giannoni E, etal: HIF-1alpha stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51: 893-904, 2011.
113. Misra RM, Bajaj MS and Kale VP: Vasculogenic Mimicry of HT1080 Tumour Cells In Vivo: Critical Role of HIF-1alpha-Neuropilin-1 Axis. PLoS One 7: e50153, 2012.
114. Jiang J, Tang YL and Liang XH: EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11: 714-723, 2011.
115. Bao B, Azmi AS, Ali S, etal: The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 1826: 272-296, 2012.
116. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
117. Xu X and Prestwich GD: Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 116: 1739-1750, 2010.
118. Keunen O, Johansson M, Oudin A, etal: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108: 3749-3754, 2011.
119. Qu B, Guo L, Ma J and Lv Y: Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system. Med Hypotheses74: 360-361, 2010.
120. Cao G, Fehrenbach ML, Williams JT, Finklestein JM, ZhuJX and Delisser HM: Angiogenesis in platelet endothelial cell adhesion molecule-1-null mice. Am J Pathol 175: 903-915, 2009.